Rizatriptan Benzoate
Product Images NDC 63629-8256

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 63629-8256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 01

A line chart showing the estimated probability of response over time (hours post-dose) for Rizatriptan Benzoate Tablets at 5 mg and 10 mg doses compared to placebo. The x-axis represents hours post-dose from 0 to 2, and the y-axis represents response probability from 0% to 100%. The graph shows increasing response probabilities with higher doses of Rizatriptan Benzoate over time, surpassing placebo.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 02

A line graph showing the estimated probability of remediation or rescue over 24 hours post-dose for placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg. The y-axis represents the probability percentage, while the x-axis indicates hours after dosing, illustrating comparative efficacy trends over time.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 03

A line graph depicting the estimated probability of response over time, measured in hours post-dose, comparing placebo and two dosage strengths (5 mg and 10 mg) of Rizatriptan Benzoate orally disintegrating tablets. The graph shows response probabilities increasing from 0 to 2 hours post-dose for each group.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 04

A Kaplan-Meier curve showing the estimated probability of clinical improvement or rescue over 24 hours post-dose for placebo and Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses. The y-axis indicates probability percentage, and the x-axis shows hours after dosing.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 05

A line graph comparing the percent effect with 95% confidence intervals over time in hours after a Stage 2 dose for Rizatriptan Benzoate Orally Disintegrating Tablets and placebo. The x-axis represents hours post dose (0.5 to 2.0), and the y-axis shows the percent effect ranging from 0 to 100.*

FDA Label Image

Cfdcf7ff E979 444f B9fe 68fb3e9495b9 88 1

Chemical structure diagram of RIZATRIPTAN BENZOATE, showing the arrangement of its atoms and bonds.*

FDA Label Image

Label Image (Lbl636298256)

Label for Rizatriptan Benzoate 10 mg ODT (orally disintegrating tablet) packaged by Bryant Ranch Prepack. The label indicates comparison to Maxalt 10 mg ODT blister pack by Panacea Biotec Ltd. It shows storage instructions at 20°-25°C (68°-77°F), a lot number 1523487, an NDC of 63629-8256-1, and a quantity of 10 tablets. The label includes a barcode and states prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.